Jaroslav Bačovský

428 total citations
51 papers, 198 citations indexed

About

Jaroslav Bačovský is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jaroslav Bačovský has authored 51 papers receiving a total of 198 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hematology, 26 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Jaroslav Bačovský's work include Multiple Myeloma Research and Treatments (46 papers), Bone health and treatments (10 papers) and Peptidase Inhibition and Analysis (8 papers). Jaroslav Bačovský is often cited by papers focused on Multiple Myeloma Research and Treatments (46 papers), Bone health and treatments (10 papers) and Peptidase Inhibition and Analysis (8 papers). Jaroslav Bačovský collaborates with scholars based in Czechia, Slovakia and Sweden. Jaroslav Bačovský's co-authors include Jiří Minařík, Tomáš Pika, Vlastimil Ščudla, Kateřina Langová, Marie Budı́ková, Karel Indrák, Ladislav Dušek, Martin Mistrík, Pavel Koranda and Marie Jarošová and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cell Death and Disease.

In The Last Decade

Jaroslav Bačovský

46 papers receiving 193 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jaroslav Bačovský Czechia 9 139 102 79 34 15 51 198
Kenneth Anderson United States 7 125 0.9× 75 0.7× 52 0.7× 24 0.7× 4 0.3× 14 205
José Antonio Queizán Spain 7 103 0.7× 74 0.7× 58 0.7× 48 1.4× 7 0.5× 13 169
Ari Pelcovits United States 7 110 0.8× 121 1.2× 68 0.9× 29 0.9× 19 1.3× 23 264
Dimuthu Perera United States 10 97 0.7× 213 2.1× 39 0.5× 35 1.0× 7 0.5× 19 343
Brett T. Brinker United States 5 37 0.3× 65 0.6× 41 0.5× 46 1.4× 12 0.8× 5 133
Christian Hosius Germany 7 59 0.4× 84 0.8× 95 1.2× 47 1.4× 11 0.7× 19 228
Ioanna Dialoupi Greece 9 106 0.8× 140 1.4× 61 0.8× 46 1.4× 8 0.5× 23 197
Terukazu Enami Japan 10 76 0.5× 76 0.7× 53 0.7× 39 1.1× 21 1.4× 16 225
Constantinos Pamboukas Greece 6 141 1.0× 252 2.5× 85 1.1× 91 2.7× 12 0.8× 10 325
Esra Meidan United States 5 26 0.2× 92 0.9× 47 0.6× 13 0.4× 5 0.3× 7 366

Countries citing papers authored by Jaroslav Bačovský

Since Specialization
Citations

This map shows the geographic impact of Jaroslav Bačovský's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaroslav Bačovský with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaroslav Bačovský more than expected).

Fields of papers citing papers by Jaroslav Bačovský

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaroslav Bačovský. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaroslav Bačovský. The network helps show where Jaroslav Bačovský may publish in the future.

Co-authorship network of co-authors of Jaroslav Bačovský

This figure shows the co-authorship network connecting the top 25 collaborators of Jaroslav Bačovský. A scholar is included among the top collaborators of Jaroslav Bačovský based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaroslav Bačovský. Jaroslav Bačovský is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Škrott, Zdeněk, Ján Gurský, Jaroslav Bačovský, et al.. (2022). A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death and Disease. 13(3). 203–203. 12 indexed citations
2.
Minařík, Jiří, Jakub Radocha, Alexandra Jungová, et al.. (2022). Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 14(20). 5165–5165. 5 indexed citations
3.
Minařík, Jiří, et al.. (2021). A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma. SHILAP Revista de lepidopterología. 9(8). e04570–e04570. 1 indexed citations
4.
5.
Minařík, Jiří, et al.. (2017). CD38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy. European Journal Of Haematology. 99(2). 186–189. 14 indexed citations
6.
Minařík, Jiří, et al.. (2017). Differential diagnosis of monoclonal gammopathies from the point of clinical practiceI. Malignant monoclonal gammopathies. Interní medicína pro praxi. 19(5). 274–278. 1 indexed citations
7.
Minařík, Jiří, Jan Hrbek, Tomáš Pika, et al.. (2016). Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies. Biomedical Papers. 160(2). 305–309. 7 indexed citations
8.
Ščudla, Vlastimil, Tomáš Pika, Jaroslav Bačovský, et al.. (2016). Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse. Clinical Lymphoma Myeloma & Leukemia. 16(6). 358–365. 3 indexed citations
9.
10.
Minařík, Jiří, Tomáš Pika, Jaroslav Bačovský, & Vlastimil Ščudla. (2013). Kryoglobulinemická vaskulitida u nemocného s mnohočetným myelomem. Interní medicína pro praxi. 14(12). 478–480.
11.
Minařík, Jiří, et al.. (2012). Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. The Scientific World JOURNAL. 2012. 1–6. 13 indexed citations
12.
Minařík, Jiří, Vlastimil Ščudla, Tomáš Pika, et al.. (2010). Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis. Leukemia Research. 35(1). 44–48. 5 indexed citations
13.
Minařík, Jiří, et al.. (2009). Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. European Journal Of Haematology. 83(6). 528–534. 3 indexed citations
14.
Ščudla, Vlastimil, et al.. (2009). Gain of chromosome arm 1q in patieznts in relapse and progression of multiple myeloma. Cancer Genetics and Cytogenetics. 192(2). 68–72. 10 indexed citations
15.
Pika, Tomáš, et al.. (2009). UNUSUAL MANIFESTATION OF MULTIPLE MYELOMA: FOCAL AFFECTION OF CENTRAL NERVOUS SYSTEM IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKAEMIA. Biomedical Papers. 153(4). 271–273. 2 indexed citations
16.
17.
Pika, Tomáš, Jiří Minařík, Marie Budı́ková, et al.. (2008). THE CORRELATION OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAIN LEVELS AND SELECTED BIOLOGICAL MARKERS IN MULTIPLE MYELOMA. Biomedical Papers. 152(1). 61–64. 4 indexed citations
18.
Büchler, Tomáš, Marta Krejčí, Adam Svobodník, et al.. (2005). Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. The Hematology Journal. 5(7). 559–564. 9 indexed citations
19.
Minařík, Jiří, et al.. (2005). EVALUATION OF PLASMA CELL PROPIDIUM-IODIDE AND ANNEXIN-V INDICES: THEIR RELATION TO PROGNOSIS IN MULTIPLE MYELOMA. Biomedical Papers. 149(2). 271–274. 4 indexed citations
20.
Bačovský, Jaroslav, Karel Indrák, Edgar Faber, et al.. (2003). Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients. The Hematology Journal. 4(5). 351–357. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth Anderson Breakdown of academic impact, for papers by José Antonio Queizán Breakdown of academic impact, for papers by Ari Pelcovits Breakdown of academic impact, for papers by Dimuthu Perera Breakdown of academic impact, for papers by Brett T. Brinker Breakdown of academic impact, for papers by Christian Hosius Breakdown of academic impact, for papers by Ioanna Dialoupi Breakdown of academic impact, for papers by Terukazu Enami Breakdown of academic impact, for papers by Constantinos Pamboukas Breakdown of academic impact, for papers by Esra Meidan
Rankless by CCL
2026